Monday, 20 Jan 2020

You are here

Recommendations for Exercise in Ankylosing Spondylitis

Australian researchers have assessed the problem of exercise in ankylosing spondylitis (AS). After posing 10 questions to 11 experts they have provided evidence and consensus-based ecommendations on exercise in AS.

After a systematic literature review on 10 clinical questions and a modified Delphi process, the expert panel met at a 2-day meeting to grade the evidence and develop expert opinion.  Key areas of interest included - assessment; monitoring; safety; disease management; AS-specific exercise; physical activity; dosage, adherence and setting. 

These recommendations provide an up-to-date, evidence-based approach to the full range of issues related to the use of exercise in AS, as well as identifying evidence gaps for further research.

Ten recommendations were developed (most of which were consensus based) around specific questions:

  1. Assessment: Individual exercise prescription should be informed by a thorough clinical assessment, which includes musculoskeletal and psychosocial factors, and AS-specific measures, including objective axial mobility and chest expansion. This may included the Bath Ankylosing Spondylitis Metrology Index (BASMI)
  2. Monitoring:  monitoring and feedback should be provided on an individual basis, to achieve confidence and competence with exercise, and to inform changing needs for exercise prescription. This is recommended at least annually, and more often as symptoms, function and mobility indicate.
  3. Safety: Physical changes from AS should be considered in all aspects of exercise prescription, especially for those with more severe or later disease - not limited to : bony change/ankylosis, balance and mobility changes, osteoporosis and cardiorespiratory consequences of the disease.
  4. Disease management: Exercise plus anti-TNFα therapy is better than anti-TNFα therapy alone (Evidence based, grade B)
  5. AS-specific exercise—Mobility: an exercise prescription with an emphasis on spinal mobility is paramount for best management of AS. Maintaining mobility of peripheral joints is also essential. (EBR grade A)
  6. AS-specific exercise—other: stretching, strengthening, cardiopulmonary and functional fitness are important components to include in a balanced exercise programme (EBR grade A).
  7. Physical activity: regular physical activity should be encouraged to promote general health, well-being and functional outcomes (EBR, grade B). No one activity has been found to be superior.  Exercise frequency, intensity, duration and type must be tailored to the person׳s assessment findings, goals and lifestyle.
  8. Dosage: exercise frequency, intensity, duration and type must be tailored to the person׳s findings, goals and lifestyle.
  9. Adherence: It is important to assess adherence with regular exercise, encourage motivation and promote ongoing self-management (EBR, grade B)
  10. Exercise setting: priority should be given to patient preference in exercise choice, to enhance adherence and optimise positive outcomes.
Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Taltz Shines in Non-Radiographic Axial Spondyloarthritis

Ixekizumab (IXE), an interleukin-17A (IL-17A) inhibitor, was recently approved for use in ankylosing spondylitis (also known as radiographic axial spondyloarthritis- axSpA). Lancet has published the results of the COAST-X study showing that ixekizumab was effective in patients with non-radiographic axial spondyloarthritis.

Best of 2019 - SEAM-PsA Study - Does Monotherapy MTX Win Despite Losing to Etanercept in Psoriatic Arthritis?

The SEAM-PsA study examined the efficacy of methotrexate monotherapy, etanercept monotherapy or the combination of MTX and ETN in psoriatic arthritis patients, and found that ETN monotherapy was equivalent to combination therapy - and that both were superior to MTX alone in clinical (ACR and MDA) and radiographic responses.

Best of 2019 - ACR/SPARTAN Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

The American College of Rheumatology (ACR), in partnership with the Spondylitis Association of America (SAA) and the Spondyloarthritis Research and Treatment Network (SPARTAN), released the 2019 Update of the Recommendations for the Treatment of Ankylosing Spondylitis (AS) and Nonradiographic Axial Spondyloarthritis (nr-axSpA).

Upadacitinib Effective in Ankylosing Spondylitis

Lancet reports that the selective JAK1 inhibitor, upadacitinib, was effective when given to patients with active ankylosing spondylitis.

Secukinumab Improves Enthesitis

Secukinumabs (SEC) effect on enthesitis in psoriatic arthritis (PsA) was studied in the FUTURE 2 and 3 studies and SEC was shown significantly reduced enthesitis by more than 65% within 14 week.